Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in...

Related Keywords

Stanford University ,California ,United States ,Stanford ,American ,Medizinische Hochschule Hannover ,Michaela Liedtke ,Gabriel Morris ,Ilya Rachman ,Los Angeles ,Mike Moyer ,Stanford Cardiovascular Institute ,Translational Research Award ,Oncology Group ,Stanford University Medicine Cancer Center Program ,American Society Of Hematology ,Lymphoma Research Foundation ,Immix Biopharma Inc ,American Society Of Clinical Oncology ,International Myeloma Society ,Company Contact ,International Society Of Amyloidosis ,Doris Duke Foundation ,Stanford Amyloid Center ,Stanford Department Of Medicine ,Young Adult Program ,Stanford University Medical Center ,Memorial Sloan Kettering Cancer Center ,Nasdaq ,Methods In Clinical Cancer Research Scholar ,Albert Einstein College Of Medicine ,Member Leukemia Committee ,Exchange Commission ,Nexcella Inc ,Nexcella Scientific Advisory Board ,Stanford University Medical ,Nexcella Scientific Advisory ,Scientific Advisory Board ,Chief Financial Officer ,Immix Biopharma ,Medical Director ,Stanford Adolescent ,Southwest Oncology ,Stanford Department ,Young Investigator Award ,American Society ,Clinical Oncology ,Clinical Cancer Research Scholar ,Fellowship Award ,Doris Duke ,International Society ,Stanford Cardiovascular ,Albert Einstein College ,Medizinische Hochschule ,Orphan Drug Designation ,Tissue Specific Therapeutic ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Markets ,